Why is BLTE down?
Down 25% from Nov 12 to Nov 20 while the S&P 500 fell 9%.
“Belite Bio Announces Extension of FDA Review Timeline for Tinlarebant.”
−1Profit
Why BLTE still beats the market over three years
Up 233% over the three years to Nov 20 while the S&P 500 rose 58%; down 25% since Nov 12.
3 reasons, from its filings, with the timeline and its peers, for Pro members.